Ovarian Germ Cell Tumors: Symptoms, Diagnosis, and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Ovarian germ cell tumors (OGCTs) arise from primordial germ cells of the ovary and account for approximately 5% of all ovarian malignancies. They are the most common ovarian malignancy in adolescents and young women under age 30. The major malignant subtypes include dysgerminoma (the most common, analogous to testicular seminoma), yolk sac tumor (endodermal sinus tumor), immature teratoma (graded I–III), embryonal carcinoma, choriocarcinoma, and mixed germ cell tumors. Benign mature cystic teratoma (dermoid cyst) is distinct and not malignant. Unlike epithelial ovarian cancers, OGCTs are highly chemosensitive and carry an excellent prognosis — even for advanced-stage disease — with cure rates exceeding 90% with appropriate treatment. Most cases present unilaterally, enabling fertility-sparing surgical management. Early diagnosis and referral to a gynecologic oncologist are critical for optimal outcomes.

OGCTs arise from aberrant development of totipotent germ cells that migrate to the gonadal ridge during embryogenesis. Unlike epithelial ovarian cancers, hereditary predisposition is less clearly defined. Gonadal dysgenesis — including 46,XY gonadal dysgenesis (Swyer syndrome) and Turner syndrome with Y chromosome mosaicism — significantly increases the risk of dysgerminoma in streak gonads, warranting prophylactic gonadectomy. Isochromosome 12p [i(12p)] is a recurrent cytogenetic abnormality seen in dysgerminoma and nonseminomatous germ cell tumors. No consistent modifiable environmental risk factors have been identified. The condition occurs predominantly in adolescents and young women (median age 16–26 for dysgerminoma), and bilateral involvement occurs in approximately 10–15% of dysgerminomas but is rare in other subtypes. A family history of germ cell tumors in first-degree relatives may slightly increase risk.

Ovarian germ cell tumors typically present acutely due to their rapid growth rate. The most common presentation is a palpable pelvic or abdominal mass causing abdominal pain or distension, occurring in over 80% of patients. Acute abdominal pain mimicking appendicitis may result from torsion of a rapidly enlarging ovary. Associated symptoms include nausea, vomiting, fever, and constipation. Yolk sac tumors and choriocarcinomas may cause isosexual precocious puberty in prepubertal girls due to HCG secretion. Irregular vaginal bleeding may occur. Ascites and pleural effusion are less common than in epithelial carcinomas. Red flags include rapidly enlarging abdominal mass, signs of ovarian torsion (sudden severe unilateral pelvic pain with nausea and vomiting), and signs of peritoneal irritation (rigidity, rebound tenderness) — all require emergency evaluation.

Diagnosis combines imaging with serum tumor markers. Transvaginal or transabdominal ultrasound typically shows a predominantly solid unilateral mass in a young woman. MRI provides superior characterization, with signal intensities consistent with specific histological subtypes (fat signal in teratoma). CT of chest, abdomen, and pelvis is performed for staging. Essential serum tumor markers include alpha-fetoprotein (AFP) — elevated in yolk sac tumors and immature teratomas — beta-HCG (elevated in choriocarcinoma and embryonal carcinoma), and lactate dehydrogenase (LDH, elevated in dysgerminoma). Karyotype analysis is recommended in all premenarchal patients to exclude gonadal dysgenesis. Definitive diagnosis requires histopathological analysis of surgical specimens. FIGO staging applies: Stage I (confined to ovaries), Stage II (pelvic extension), Stage III (abdominal dissemination), Stage IV (distant metastasis). Preoperative evaluation should always include tumor marker panel.

Treatment emphasizes fertility preservation given the young patient population, following NCCN and ESMO guidelines. Standard surgery for unilateral disease is salpingo-oophorectomy with comprehensive staging — omentectomy, peritoneal biopsies, and pelvic and para-aortic lymph node sampling. The contralateral ovary and uterus are preserved whenever oncologically feasible. Dysgerminoma stage IA and immature teratoma stage IA grade 1 after complete resection may be observed without adjuvant therapy. All other stages and histologies receive BEP chemotherapy (bleomycin 30 units day 1, 8, 15; etoposide 100 mg/m² days 1–5; cisplatin 20 mg/m² days 1–5) — typically 3–4 cycles, achieving remission in over 90% of patients. Salvage chemotherapy for recurrence includes TIP (paclitaxel, ifosfamide, cisplatin) or high-dose chemotherapy with autologous stem cell rescue for chemorefractory disease. Radiotherapy is rarely used but may be considered for isolated relapsed dysgerminoma.

Ovarian germ cell tumors have an excellent prognosis owing to their remarkable sensitivity to cisplatin-based chemotherapy. Overall 5-year survival exceeds 90% across all stages for all malignant subtypes combined. Stage I dysgerminoma after complete surgical staging has a 5-year survival approaching 100%. Advanced-stage dysgerminoma (Stage III–IV) treated with BEP chemotherapy achieves 5-year survival of 85–90% — among the highest cure rates of any advanced gynecological malignancy. Yolk sac tumors, immature teratomas, and other non-dysgerminomatous subtypes also have favorable prognosis: 5-year survival of 75–85% for advanced stages with BEP. Key prognostic factors include histological subtype (dysgerminoma most favorable), FIGO stage, serum tumor marker levels (AFP, hCG, LDH) at diagnosis and their rate of normalization on treatment, and completeness of surgical resection. Complete normalization of tumor markers after 2–3 cycles of BEP is a strong predictor of cure. Relapsed OGCT is salvageable in 30–40% with TIP (paclitaxel, ifosfamide, cisplatin) or high-dose chemotherapy with ASCT. Fertility is preserved in most patients who receive unilateral salpingo-oophorectomy; long-term reproductive outcomes are generally excellent, with studies showing >80% of patients retaining regular menstrual function and the ability to conceive. Bleomycin-related pulmonary toxicity and cisplatin-related nephrotoxicity and ototoxicity are important late effects that require monitoring during and after treatment completion.

There are no established preventive measures for sporadic ovarian germ cell tumors in the general population. In patients with gonadal dysgenesis and Y chromosome material, prophylactic gonadectomy is recommended before puberty, as the lifetime risk of malignant OGCT in this population exceeds 30%. Post-treatment surveillance with regular clinical examination, pelvic ultrasound, and serial tumor markers (AFP, beta-HCG, LDH) is recommended every 3 months for the first 2 years, then every 6 months up to 5 years. Long-term fertility outcomes after fertility-sparing surgery are generally favorable, with most women retaining regular menstrual function and the ability to conceive. Survivors require monitoring for chemotherapy-related late effects including bleomycin-induced pulmonary toxicity and cisplatin-related nephrotoxicity and ototoxicity.

Young women and adolescent girls with a rapidly enlarging pelvic or abdominal mass, acute lower abdominal pain, or signs of ovarian torsion (sudden severe pelvic pain with nausea and vomiting) need emergency evaluation immediately. Isosexual precocious puberty in a prepubertal girl — breast development, pubic hair, or vaginal bleeding before age 8 — warrants urgent endocrine and oncologic evaluation to exclude an HCG-secreting germ cell tumor. Any ultrasound-detected solid ovarian mass in an adolescent or young woman requires referral to a gynecologic oncologist. Girls with known gonadal dysgenesis or Y chromosome mosaicism need prompt referral for risk assessment and timing of prophylactic gonadectomy. Markedly elevated AFP or beta-HCG on routine blood work also warrants urgent specialist review.